Prosecution Insights
Last updated: April 19, 2026

Examiner: LEE, JAE W

Tech Center 1600 • Art Units: 1632 1656 1678

This examiner grants 66% of resolved cases

Performance Statistics

65.5%
Allow Rate
+5.5% vs TC avg
438
Total Applications
+38.5%
Interview Lift
1119
Avg Prosecution Days
Based on 412 resolved cases, 2023–2026

Rejection Statute Breakdown

4.1%
§101 Eligibility
25.3%
§102 Novelty
28.6%
§103 Obviousness
31.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17929124 METHODS AND COMPOSITIONS FOR MODULATING A GENOME Non-Final OA FLAGSHIP PIONEERING INNOVATIONS VI, LLC
17786168 GENOME EDITING USING REVERSE TRANSCRIPTASE ENABLED AND FULLY ACTIVE CRISPR COMPLEXES Final Rejection MASSACHUSETTS INSTITUTE OF TECHNOLOGY
17725407 METHODS AND COMPOSITIONS FOR THE POSITIVE SELECTION OF PROTEIN DESTABILIZERS Final Rejection Dana-Farber Cancer Institute, Inc.
17816637 TRANSFORMATIONAL IMMUNE DIAGNOSTICS Final Rejection Arizona Board of Regents on Behalf of Arizona State University
17997453 ALBUMIN DRUG CONJUGATES AND USE THEREOF FOR THE TREATMENT OF CANCER Non-Final OA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
17737044 LIGHT-GENERATING FUSION PROTEINS CAPABLE OF SELF-ACTIVATION Non-Final OA Technion Research & Development Foundation Limited
18507709 Engineered CRISPR-Cas9 nucleases with Altered PAM Specificity Final Rejection The General Hospital Corporation
18137921 INTRINSICALLY DISORDERED PROTEINS FOR EXTRACTION OF NUCLEIC ACIDS Non-Final OA UNM Rainforest Innovations
17905583 IN VIVO mRNA DISPLAY: LARGE-SCALE PROTEOMICS BY NEXT GENERATION SEQUENCING Non-Final OA The Trustees of Columbia University in the City of New York
18040810 CELLULOSE BINDING DOMAIN (CBD) CELL EFFECTOR PROTEIN (CEP) CHIMERA, FOR THE TISSUE ENGINEERING Non-Final OA Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
17927164 SUBTILASE VARIANTS AND COMPOSITIONS COMPRISING SAME Non-Final OA Novozymes A/S
18037934 THERMOTOLERANT PROTEIN GLUTAMINASE Non-Final OA AMANO ENZYME INC.
18161654 RECOMBINATION-BASED DNA ASSEMBLY METHODS AND COMPOSITIONS Non-Final OA INTEGRATED DNA TECHNOLOGIES, INC.
17794320 METHODS OF NUCLEIC ACID SYNTHESIS Non-Final OA Nuclera Ltd
17905911 Engineered PlyAB Nanopores and Uses Thereof Non-Final OA Rijksuniversiteit Groningen
18065810 NOVEL MICROORGANISM FOR POLYSTYRENE BIODEGRADATION Final Rejection INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
17750061 CHEMICALLY INDUCIBLE POLYPEPTIDE POLYMERIZATION Non-Final OA Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
18058712 COMPOSITIONS AND METHODS FOR INHIBITING VASCULAR SMOOTH MUSCLE CELL PROLIFERATION Non-Final OA Westfälische Wilhelms-Universität Münster
17628023 METHOD FOR EVALUATING STATE OF CELL DIFFERENTIATION Non-Final OA Cyto-Facto Inc.
17587643 SYSTEMS AND METHODS FOR ASSESSING A TARGET MOLECULE Non-Final OA AXBIO INC.
17276619 DEPLETING UNWANTED RNA SPECIES Non-Final OA QIAGEN Sciences, LLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month